Safety of lacto‐N‐fucopentaose I/2’‐fucosyllactose (LNFP‐I/2’‐FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283 DOI Creative Commons
Dominique Turck, Torsten Bohn,

Jacqueline Castenmiller

et al.

EFSA Journal, Journal Year: 2023, Volume and Issue: 21(12)

Published: Dec. 1, 2023

Following a request from the European Commission, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion lacto-N-fucopentaose I (LNFP-I)/2'-fucosyllactose (2'-FL) mixture as novel food (NF) pursuant Regulation (EU) 2015/2283. The NF is mainly composed of human-identical milk oligosaccharides (HiMO) LNFP-I 2'-FL, but it also contains d-lactose, lacto-N-tetraose, difucosyllactose, 3-fucosyllactose, fructose isomer, 2'-fucosyl-d-lactulose, l-fucose 2'-fucosyl-d-lactitol, small fraction other related saccharides. produced by fermentation genetically modified strain (Escherichia coli K-12 DH1 MDO MP2173b) E. (DSM 4235). information provided identity, manufacturing process, composition specifications does not raise safety concerns. applicant intends add in variety foods, including infant formula (IF) follow-on formula, foods for infants toddlers, special medical purposes supplements (FS). target population general population. anticipated daily intake use IF similar estimated natural mean highest breastfed infants. Overall, ingredient at maximum proposed levels unlikely exceed level body weight basis. basis expected be safe groups. 2'-FL generally rather low. FS intended if with added components or human (for young children) are consumed same day. concludes that NF, under conditions use.

Language: Английский

Interactions of human milk oligosaccharides with the immune system DOI Creative Commons

A. Slater,

Rita M. Hickey, Gavin P. Davey

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 14, 2025

Human milk oligosaccharides (HMOs) are abundant, diverse and complex sugars present in human breast milk. HMOs well-characterized barriers to microbial infection by modulating the microbiome they also thought be nutritionally beneficial infant. The structural variety of over 200 HMOs, including neutral, fucosylated sialylated forms, allows them interact with immune system various ways. Clinically, impact allergic diseases, reducing autoimmune inflammatory responses, offer support preterm infant health. This review examines HMO composition associated immunomodulatory effects, interactions cell receptors gut-associated responses. These properties highlight potential for use early stage development as novel immunotherapeutics. research is rapidly evolving promises innovative treatments immune-related conditions improved health outcomes.

Language: Английский

Citations

2
Structure, Function, Synthesis and Improved Strategies of Fucosylated Human Milk Oligosaccharides and Their Future Perspectives: A Review DOI

Ya-Ya Yang,

Shunli Jing,

Le Zhang

et al.

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106584 - 106584

Published: April 1, 2025

Language: Английский

Citations

0
Scientific and technical assistance report on the evaluation of human‐identical milk oligosaccharides (HiMOs) as novel foods DOI Open Access
Dominique Turck, Paolo Colombo, Estefanía Noriega Fernández

et al.

EFSA Supporting Publications, Journal Year: 2024, Volume and Issue: 21(9)

Published: Sept. 1, 2024

Abstract EFSA was asked by the European Commission to provide scientific and technical assistance on evaluation of human‐identical milk oligosaccharides (HiMOs) as novel foods (NFs). In recent years, number authorisations HiMOs NFs has markedly increased, which may lead situations multiple concurrent uses. Since safety assessment is based comparison with ‘natural’ intake human (HMOs), i.e. HMO from in exclusively breastfed infants, a scoping literature review outsourced update database mean concentrations single total HMOs milk, relevant intakes were thus updated. It noted that infants up 16 weeks age fed infant formula, when adding all assessed at their highest maximum use levels across production methods, resulting daily sum are within natural range. These also estimated (DietEx) for most exposed population groups (i.e., young children) considering those food categories contribution overall HiMO follow‐on formulae, ready‐to‐eat meals, yoghurt cow milk). The P95 unlikely be higher than intakes. However, any possible would not necessarily imply concern since such estimates represent an upper end average can concluded currently there no concerns authorised or combined Nonetheless, consideration increased interest NFs, simplified but realistic approach proposed case new extensions already HiMOs.

Language: Английский

Citations

2
Safety of lacto‐N‐fucopentaose I/2’‐fucosyllactose (LNFP‐I/2’‐FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283 DOI Creative Commons
Dominique Turck, Torsten Bohn,

Jacqueline Castenmiller

et al.

EFSA Journal, Journal Year: 2023, Volume and Issue: 21(12)

Published: Dec. 1, 2023

Following a request from the European Commission, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion lacto-N-fucopentaose I (LNFP-I)/2'-fucosyllactose (2'-FL) mixture as novel food (NF) pursuant Regulation (EU) 2015/2283. The NF is mainly composed of human-identical milk oligosaccharides (HiMO) LNFP-I 2'-FL, but it also contains d-lactose, lacto-N-tetraose, difucosyllactose, 3-fucosyllactose, fructose isomer, 2'-fucosyl-d-lactulose, l-fucose 2'-fucosyl-d-lactitol, small fraction other related saccharides. produced by fermentation genetically modified strain (Escherichia coli K-12 DH1 MDO MP2173b) E. (DSM 4235). information provided identity, manufacturing process, composition specifications does not raise safety concerns. applicant intends add in variety foods, including infant formula (IF) follow-on formula, foods for infants toddlers, special medical purposes supplements (FS). target population general population. anticipated daily intake use IF similar estimated natural mean highest breastfed infants. Overall, ingredient at maximum proposed levels unlikely exceed level body weight basis. basis expected be safe groups. 2'-FL generally rather low. FS intended if with added components or human (for young children) are consumed same day. concludes that NF, under conditions use.

Language: Английский

Citations

4